Columbus register at the CNMV its second Fund , Columbus Life Science Fund II

Columbus Life Science Fund II will complete the first closing by end of February with a target of €70M

 

MADRID – February 4, 2019

Columbus Venture Partners a leading biotechnology venture capital firm in Spain, today announced the registration at the CNMV of its second fund Columbus Life Science Fund II, FCR with a target of €70M. First closing will take place by the end of February.
Columbus Life Science Fund II has a strategy similar to predecessor fund Columbus INNVIERTE Life Science (currently under divestment).

Columbus aims to invest in biotechnology advanced therapies opportunities with a focus on both therapies and industrial development globally with a special interest in Spain. The fund will finance up to seven projects in advanced therapies with disruptive products, platforms or technologies that address unmet medical needs.
“Innovation in life sciences is an attractive sector for specialized investors”, said Javier Garcia, managing partner at Columbus Venture Partners. “We will keep the direction established in Fund I, with a strong commitment to advanced therapies, and significant investment in industrial infrastructure and technologies that are key for those medical advances”.

As it happened in Columbus INNVIERTE Life Sciences, Columbus Life Science Fund II will co-invest with specialized international investors and corporate venture funds.

About Columbus Venture Partners

Columbus Venture Partners is a Spanish independent venture capital that brings a unique approach for investing in outstanding early-stage and high growth opportunities in the life science industry of Spain.
Our team includes solid and internationally experienced investment professionals with a deep scientific, medical and business development background combined with a proven experience in building and investing in companies to accelerate their commercialization.

Columbus launched its first €41M fund (Columbus INNVIERTE Life Science, FCR) in April 2016. Columbus has invested in 5 companies, PTS, Radioterapia de Protones, Vivet Therapeutics, Aura Biosciences, and Viralgen Vector Core.
The combination of industry possibilities and investment experience will provide Limited Partner investors in the Fund a level of professionalism and deep expertise that is essential for success in this field.

Columbus Venture Partners is a Spanish leading venture capital firm specialized in biotechnology, with over €100 M under management through its two funds: Columbus INNVIERTE Life Science, FCR and Columbus Life Science Fund II. Columbus Life Science Fund II will announce its first investments in the upcoming months

For more information visit, www.columbusvp.com